[1] Filip PV, Cuciureanu D, Diaconu LS, et al.  MALT lymphoma: epidemiology, clinical diagnosis and treatment[J]. J Med Life, 2018, 11(3): 187-193.   doi: 10.25122/jml-2018-0035
[2] Kuo SH, Cheng AL.  Helicobacter pylori and mucosa-associated lymphoid tissue: what's new[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013: 109-117.   doi: 10.1182/asheducation-2013.1.109
[3] Perry C, Herishanu Y, Metzer U, et al.  Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma[J]. Eur J Haematol, 2007, 79(3): 205-209.   doi: 10.1111/j.1600-0609.2007.00895.x
[4] 蒋冲, 孙一文, 滕月, 等.  胃黏膜相关淋巴组织淋巴瘤 18F-FDG PET/CT影像学与消化内镜对照研究[J]. 中华核医学与分子影像杂志, 2021, 41(11): 660-663.   doi: 10.3760/cma.j.cn321828-20200623-00249
Jiang C, Sun YW, Teng Y, et al.  Comparison of 18F-FDG PET/CT and digestive endoscopy findings in gastric mucosa-associated lymphoid tissue lymphoma[J]. Chin J Nucl Med Mol Imaging, 2021, 41(11): 660-663.   doi: 10.3760/cma.j.cn321828-20200623-00249
[5] Schöder H, Noy A, Gönen M, et al.  Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma[J]. J Clin Oncol, 2005, 23(21): 4643-4651.   doi: 10.1200/JCO.2005.12.072
[6] Buck AK, Serfling SE, Lindner T, et al.  CXCR4-targeted theranostics in oncology[J]. Eur J Nucl Med Mol Imaging, 2022, 49(12): 4133-4144.   doi: 10.1007/s00259-022-05849-y
[7] Chatterjee S, Azad BB, Nimmagadda S.  The intricate role of CXCR4 in cancer[J]. Adv Cancer Res, 2014, 124: 31-82.   doi: 10.1016/B978-0-12-411638-2.00002-1
[8] Stollberg S, Kämmerer D, Neubauer E, et al.  Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin[J]. J Cancer Res Clin Oncol, 2016, 142(11): 2239-2247.   doi: 10.1007/s00432-016-2220-6
[9] Duell J, Krummenast F, Schirbel A, et al.  Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET/CT[J]. J Nucl Med, 2021, 62(10): 1415-1421.   doi: 10.2967/jnumed.120.257279